Alembic Pharmaceuticals Ltd., which reported a sturdy set of numbers for the fiscal fourth quarter ended March 2019, has outlined a broad vision for its China joint venture, though management commentary appeared cautiously optimistic, underscoring it is still early days and that China's regulations are still evolving.
“It's a massive market where the government is doing a lot of interesting stuff in terms of access to healthcare,” Pranav Amin, Alembic’s managing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?